| Literature DB >> 35713309 |
Reza Rahmanzadeh1,2,3, Riccardo Galbusera1,2,3, Po-Jui Lu1,2,3, Erik Bahn4, Matthias Weigel1,2,3,5, Muhamed Barakovic1,2,3, Jonas Franz4,6,7, Thanh D Nguyen8, Pascal Spincemaille8, Simona Schiavi9, Alessandro Daducci9, Francesco La Rosa10,11, Martina Absinta12,13, Pascal Sati14,15, Meritxell Bach Cuadra10,11, Ernst-Wilhelm Radue1,2, David Leppert1,3, Jens Kuhle1,3, Ludwig Kappos1,3, Wolfgang Brück4, Daniel S Reich14, Christine Stadelmann4, Yi Wang8, Cristina Granziera1,2,3.
Abstract
OBJECTIVES: Neuropathological studies have shown that multiple sclerosis (MS) lesions are heterogeneous in terms of myelin/axon damage and repair as well as iron content. However, it remains a challenge to identify specific chronic lesion types, especially remyelinated lesions, in vivo in patients with MS.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35713309 PMCID: PMC9527017 DOI: 10.1002/ana.26441
Source DB: PubMed Journal: Ann Neurol ISSN: 0364-5134 Impact factor: 11.274
Clinical Characteristics of Patients and Healthy Subjects
| Cohort type | Patient with MS | Healthy subjects | |
|---|---|---|---|
| Sex, n (male/female) | Cross‐sectional | 115 (48/67) | 76 (31/45) |
| Longitudinal | 49 (13/27) | ‐ | |
| Postmortem | 3 (2/1) | ‐ | |
| Age, yr, mean ± SD | Cross‐sectional | 46 ± 14 | 35 ± 13 |
| Longitudinal | 43 ± 14 | ‐ | |
| Postmortem | 58 ± 5 | ‐ | |
| EDSS score, median (range) | Cross‐sectional | 3.14 (0–8) | ‐ |
| Longitudinal | 2.5 (1–7) | ‐ | |
| Postmortem | 4 (2.5–8) | ‐ | |
| Disease course (RRMS/PMS) | Cross‐sectional | 76/39 | ‐ |
| Longitudinal | 32/8 | ‐ | |
| Postmortem | 0/3 | ‐ | |
| Disease duration, yr, mean ± SD | Cross‐sectional | 9.2 (10.41) | ‐ |
| Longitudinal | 8.93 (10.09) | ‐ | |
| Postmortem | 16 (7.54) | ‐ | |
| Disease‐modifying therapy (n) | Cross‐sectional |
Untreated (13) Interferon‐beta (1) Glatiramer acetate (1) Dimethyl fumarate (15) Fingolimod (9) Natalizumab (4) Rituximab (13) Ocrelizumab (55) Siponimod (2) Teriflunomide (2) | ‐ |
| Longitudinal |
Untreated (3) Dimethyl fumarate (9) Fingolimod (1) Natalizumab (2) Rituximab (3) Ocrelizumab (22) |
EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; PMS = progressive multiple sclerosis; RRMS = relapsing‐remitting multiple sclerosis.
Figure 1Design of the in vivo and postmortem parts of the study. MS = multiple sclerosis; PMS = progressive multiple sclerosis; QSM = quantitative susceptibility mapping; RRMS = relapsing‐remitting multiple sclerosis. [Color figure can be viewed at www.annalsofneurology.org]
Figure 2QSM lesion types and their distribution in patients with MS. (A–E) Exemplary QSM lesion types (A = iso‐intense, B = hypo‐intense, C = hyperintense, D = hypo‐rim, E = PRL). Table in Figure 2: distribution of the different QSM lesion types (%) in patients with RRMS and PMS. PMS = progressive multiple sclerosis; QSM = quantitative susceptibility mapping; RRMS = relapsing‐remitting multiple sclerosis. [Color figure can be viewed at www.annalsofneurology.org]
Figure 3Lesions excluded from the QSM classification. (A) Confluent lesions; (B) lesions crossed by one/more vessels; (C) lesions in artifacts area. Lesions are magnified in a rectangle on the bottom right and indicated with a red arrow. QSM = quantitative susceptibility mapping. [Color figure can be viewed at www.annalsofneurology.org]
Figure 4Quantitative susceptibility, MWF, and NDI in QSM lesion types. (A) Average susceptibility in WMLs, NAWM, and WM‐HCs. (B) Lesion‐wise relative susceptibility of WMLs compared to PPWM. (C) Comparison of mean relative susceptibility values among QSM lesion types. (D–F) Comparison of susceptibility, MWF, and NDI values among QSM lesion types. (G–I) GMM clustering of WMLs using mean lesion MWF, NDI, and susceptibility. *p < 0.05; **p < 0.001; ***p < 0.0001. GMM = Gaussian Mixture Model; MWF = myelin water fraction; NAWM = normal‐appearing white matter; NDI = neurite density index; ppb = parts per billion; PPWM = peri‐plaque white matter; QSM = quantitative susceptibility mapping; WM = white matter; WM‐HCs = white matter healthy controls; WML = white matter lesions. [Color figure can be viewed at www.annalsofneurology.org]
Figure 5Lesion size comparison across QSM lesion types. *p < 0.05; **p < 0.001; ***p < 0.0001. Iso = iso‐intense; ns = not significant; QSM = quantitative susceptibility mapping.
Figure 6MWF changes in iso‐ and hypo‐intense lesions at follow‐up (TP2) compared to baseline (TP1). (A) MWF increases in the majority of lesions that are hyperintense at TP1 and iso‐intense at TP2. (B) MWF is stable in lesions that are iso‐intense at TP1 and hypo‐intense at TP2. MWF = myelin water fraction; TP1 = timepoint1; TP2 = timepoint2. [Color figure can be viewed at www.annalsofneurology.org]
Figure 7Histopathology and postmortem QSM of remyelinated lesions. A1–D1: MBP (brown)‐MHC II (blue) double IHC in exemplary fully (B‐1) or partially (A1, C1, D1) remyelinated lesions. A2–D2: DAB‐enhanced TBB (brown) ‐ MHC II (blue) staining showing macrophages/activated microglia containing (D1; red arrow) or lacking iron (A1–C1; yellow arrow); A3–D3: BCAS1 IHC showing non‐compact myelin and, in D‐3, newly formed myelinating oligodendrocytes; A4–D4: postmortem QSM showing fully (B‐1) or partially (A1, C1, D1) remyelinated lesions. [Color figure can be viewed at www.annalsofneurology.org]
Figure 8Histopathology and postmortem QSM of chronic inactive and chronic active lesions. E1–F1: MBP ‐ MHC II staining of chronic inactive lesions. E2–F2: TBB (brown) ‐ MHC II (blue) staining of macrophages/activated microglia containing (E2; red arrow) or lacking iron (F2; yellow arrow). E‐3, F‐3: Postmortem QSM showing a corresponding hyperintensity for chronic inactive lesions. G1–H1: MBP ‐ MHC II IHC of chronic active lesions showing extensive demyelination. G2–H2: TBB (brown) ‐ MHC II (blue) staining showing iron‐laden macrophages/activated microglia at the lesion edge (red arrow). G‐3, H‐3: Postmortem QSM revealing a hyperintense paramagnetic rim in chronic active lesions. BCAS1 = breast carcinoma‐amplified sequence 1; IHC = immunohistochemistry; MBP = myelin basic protein; MHC II = major histocompatibility complex II; QSM = quantitative susceptibility mapping; TBB = DAB‐enhancedTurnbull's blue. [Color figure can be viewed at www.annalsofneurology.org]
Sensitivity and Specificity of QSM Classification to Distinct Histopathological MS Lesion Types
| Histopathological MS lesion types | QSM‐lesion phenotype | QSM classification sensitivity | QSM classification specificity |
|---|---|---|---|
| Remyelinated | Iso‐/hypo‐intense | 88.89% | 100% |
| Chronic inactive | Hyperintense | 71.43% | 92.00% |
| Chronic active | Rim+ lesions | 92.86% | 86.36% |
QSM = quantitative susceptibility mapping; MS = multiple sclerosis.